Genomics and Genetic Medicine Markets Projected to Reach USD 123 Billion by 2035
Genomic medicine market is projected to reach USD 123 billion by 2035; AI in genomics USD 6.5 billion; viral vector manufacturing USD 15.83 billion. Gene therapy trials drive growth.
Multiple genomics and genetic medicine markets are projected to expand at double-digit rates through 2035, driven by precision medicine, next-generation sequencing, and the commercialization of gene-based therapies. The genomic medicine market is valued at USD 33.3 billion in 2025 and is expected to reach USD 123 billion by 2035, growing at a CAGR of 14.64% over 2026–2035. The AI in genomics market is estimated at USD 0.6 billion in 2025 and is projected to reach USD 6.5 billion by 2035, expanding at a CAGR of 27.8%.
In the gene therapy space, more than 1,200 gene therapy clinical trials were active worldwide in 2025, with over 70% utilizing viral vectors, particularly adeno-associated virus (AAV) and lentiviral platforms. More than 30 viral vector-based gene therapies had reached commercial launch globally, with oncology and rare genetic disorders accounting for over 80% of approved indications. The viral vector manufacturing market, valued at USD 2.23 billion in 2025, is anticipated to grow to USD 15.83 billion by 2035, registering a CAGR of 21.65% over the 2026–2035 forecast period.
In the viral vector manufacturing market, cancer accounted for 48.25% of market revenue in 2025, while genetic disorders are projected to register the fastest growth at a CAGR of 18.14% through 2035. Gene therapy remained the leading application with a 55.31% revenue share in 2025, and AAV vectors captured 34.23% of market revenue. In-house manufacturing represented 51.68% of global revenue in 2025, while contract development and manufacturing organizations are anticipated to be the fastest-growing manufacturing model, expanding at a 17.44% CAGR. In 2025, global contract manufacturing organizations invested over USD 5 billion to expand viral vector production facilities, commissioning more than 40 new GMP manufacturing suites.
The third-generation sequencing technology market is expected to grow from $6 billion in 2025 at a CAGR of 16% and surpass $33 billion in 2030, with North America the largest region at $12 billion in 2030 and nanopore sequencing the largest segment, accounting for 52% or $17 billion of the total. The genomic biomarkers market is anticipated to reach $19.33 billion by 2030, corresponding to a CAGR of 17.2%. The gene expression analysis market is poised to grow from USD 4.23 billion in 2026 to USD 5.93 billion by 2031, expanding at a CAGR of 7%. In October 2025, Guardant Health formed a strategic partnership with Zephyr AI to accelerate the discovery of new cancer biomarkers by combining Guardant Health's molecular and real-world oncology datasets with Zephyr AI's AI and machine learning analytics platform.
The global DNA and gene cloning services market was estimated to be worth USD 3.045 billion in 2025 and is anticipated to reach USD 14.55 billion by 2035, expanding at a CAGR of 16.93%. North America is expected to generate the highest revenue during the forecast period, while Asia Pacific is expected to grow at the fastest rate.
In the genomic medicine market, the oncology segment dominated in 2025 with an approximately 38% share, with the rare genetic disorders segment the fastest-growing. Next-generation sequencing dominated the technology segment with about 52% share in 2025, and the instruments and equipment segment held roughly 44% of the products and services market. North America accounted for a 42.62% revenue share of the total genomic medicine market in 2025, and the Asia-Pacific region is the fastest-growing segment globally. The U.S. genomic medicine market was valued at USD 9.93 billion in 2025 and is expected to reach USD 32.9 billion by 2035, growing at a CAGR of 12.74%, while the Europe market is estimated at USD 9.86 billion in 2025 and projected to reach USD 34.7 billion by 2035.